Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease
Contract to support manufacturing and a Phase 1 clinical trial
Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
The COVID-19 pandemic has reemphasized the need to identify safe
IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus
Staphylococcus aureus causes a wide range of diseases from skin infections
Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques
Staphylococcus aureus is a leading cause of significant morbidity and mortality
Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization
The severe death toll caused by the recent outbreak of
Gary Nabors, Ph.D. Joins Integrated BioTherapeutics Inc. as Executive Vice President and Chief Development Officer
IBT is pioneering the development of the first multivalent toxoid-based
Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update
Copenhagen, Denmark, 06 January 2020 - Today, the Novo Holdings REPAIR Impact Fund
Efficacy of Active Immunization With Attenuated α-Hemolysin and Panton-Valentine Leukocidin in a Rabbit Model of Staphylococcus aureus Necrotizing Pneumonia
Staphylococcus aureus is a common pathogen causing infections in humans
Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes persistent
Rational Design of Toxoid Vaccine Candidates for Staphylococcus aureus Leukocidin AB (LukAB)
Staphylococcus aureus (SA) infections cause high mortality and morbidity in humans.
